Monoclonal antibodies are currently used in the diagnosis of gynecologic malignancies by way of immunohistochemical assays, serum assays, and in situ radiolocalization of carcinoma lesions. Among them is MAb B72.3, generated against a human tumor-associated antigen 
INTRODUCTION
Endometrial and ovarian carcinoma together are responsible for 19 percent of all malignancies in women, with 39,000 and 18,000 new cases diagnosed each year, respectively. Ovarian carcinoma is the fourth most frequent cause of cancer death in women, and the leading cause of gynecologic cancer death in the U.S. [1] , despite recent advances in therapy [2] . Prognosis is critically dependent on the clinical and surgical stages of the disease. Initial detection is often delayed because of the asymptomatic nature of the disease; tumors have metastasized either regionally or intraperitoneally in two-thirds of all cases at the time of initial diagnosis [2] .
The use of immunoglobulins in the diagnosis of gynecologic carcinoma may be divided into three main areas: (a) immunohistochemical and immunocytochemical assays, (b) serum assays, and (c) the use of radiolabeled monoclonal antibody (MAb) to detect carcinoma lesions in situ. Several MAbs reactive with various tumor-associated antigens (TAA) have demonstrated reactivity with gynecologic cancers, including ovarian, endometrial, and cervical neoplasms [3] [4] [5] [6] [7] [8] . Some of the more extensively characterized monoclonal antibodies that show reactivity to ovarian carcinoma are shown in Table 1 . Some of these antibodies react preferentially with tumors of non-mucinous epithelial origin and others react preferentially with mucinous ovarian [6] . OC125 appears to demonstrate cell surface binding to an antigen that exhibits better than 90 percent correlation with disease regression or progression. MAb OC 133 detects a separate antigen and binds predominately to serous ovarian neoplasms [9] . It is reactive with endometrium and endocervix but not with normal ovary or fallopian tube. Antibodies ID3 and ID5 are representative of the group of antibodies reacting with mucinous ovarian carcinoma; these two antibodies bind to extracts of undifferentiated mucinous ovarian carcinoma but not to those extracts tested of normal ovary, human serum, benign mucinous tumors, non-epithelial ovarian carcinomas, or other malignant neoplasms [10] . MAb OVB3 raised against OVCAR-3 cells shows reactivity with both mucinous and serous cystadenocarcinoma (but not normal ovary) and reacts with 4/4 human ovarian cancer cell lines [11] . MAb anti-carbohydrate (anti-CA 19-9) also reacts with both mucinous and serous ovarian carcinomas [12] . Two MAbs (MOvI and MOv2) were generated, using a membrane preparation of a mucinous ovarian cystadenocarcinoma [ 13] . MOv2 reacts with the vast majority of mucinous, serous, and endometrioid carcinomas, as well as benign serous and mucinous cystadenomas and some normal epithelia [14] . Using a (27) aAdapted from [22] bNumbers in parentheses show percentage.
poorly differentiated ovarian carcinoma as immunogen, MAbs MOv 16, MOv 18, and MOvi9 were generated [15] ; the latter two show restricted specificity for ovarian carcinomas and cystadenomas. Several MAbs originally directed against human breast cancer have shown crossreactivity with human ovarian neoplasms. For example, HMFG1 and HMFG2, directed against a component of human milk fat globule membranes, react strongly with adenocarcinoma of the ovary [16] . Four MAbs originally obtained against human breast cancer cells, 260F9, 454C11, 280D11, and 245E7, also cross-react with ovarian carcinoma cell lines [17] . MAb 454A12 [18] and MAb HB21 [19] , directed against human transferrin receptor, have been conjugated to toxins and show anti-ovarian tumor activity in vitro [19] , using OVCAR cell lines and in a nude mouse model [18] .
Monoclonal antibody B72.3 [20] was developed by the immunization of mice with membrane-enriched fraction of a metastatic breast carcinoma. It has demonstrated reactivity with a mucin-like molecule of high molecular weight [21] , termed tumorassociated glycoprotein (TAG-72). MAb B72.3 has been reacted with a variety of human adult and fetal tissues, using avidin-biotin-complex (ABC) immunohistochemical techniques to evaluate the expression of the reactive TAG-72 antigen [22] . Using formalin-fixed, paraffin-embedded tissues or frozen sections, MAb B72.3 has demonstrated reactivity with several types of carcinoma (Table 2) , including most common epithelial ovarian carcinomas, endometrial carcinomas, colorectal adenocarcinomas, carcinomas of the breast, and non-small cell lung carcinomas, as well as the majority of pancreatic and gastric carcinomas [22, 23] . , an antigen first identified in an ovarian carcinoma cell line [6] , can be detected using MAb OC125 with frozen sections in the majority of non-mucinous ovarian carcinomas [24] . Using frozen tissue sections and modified ABC-immunoperoxidase techniques, Thor et al. demonstrated that MAb B72.3 and MAb OC 125 recognize distinct antigenic determinants and are non-coordinately expressed [3] . MAb B72.3 is minimally or non-reactive with benign lesions of the colon, breast, and ovary or with a variety of normal adult tissues [22] . An exception is the reaction of MAb B72.3 with normal secretory endometrium (detailed below, [23] ). The pancarcinoma distribution of TAG-72 and lack of significant [3] . Various histologic types of malignant ovarian tumors were reacted with purified immunoglobulin preparations of MAb B72.3, using the ABC immunohistochemical technique [25] . All 57 primary and 41 of 44 metastatic common epithelial tumors contained tumor cells that were immunoreactive with MAb B72.3. The percentages of cellular reactivity for epithelial tumors ranged from 1 to 100 percent for primary tumors and from 0 to 95 percent for metastatic lesions (Table 3) Some heterogeneity of TAG-72 expression was noted between primary and metastatic masses, among various metastases, and within single tumor masses. There was no strict correlation between the percentage of cellular reactivity with MAb B72.3 and aAdapted from [23] bWhere available the degree of histologic differentiation for either serous or mucinous cystadenocarcinomas. There was a trend, however, for those tumors that were least differentiated (assigned to the undifferentiated tumor category) to show the lowest cellular reactivity with MAb B72.3 in both primary and metastatic sites [3] . Synchronous metastases from 19 of 20 cases showed similar levels of TAG-72 as in the primary epithelial neoplasm [26] . REACTIVITY OF MAb B72.3 vs. ENDOMETRIAL NEOPLASMS The expression of TAG-72 in endometrial carcinomas [23] was studied using MAb B72.3 and a modification of ABC immunoperoxidase methods [25] . Thirty-two of 32 cases of endometrial adenocarcinoma were reactive, although heterogeneity in the expression of TAG-72 by malignant epithelial cells was observed. These cases could be separated into two groups, based on percentage of cellular reactivity: nineteen cases showed >75 percent cellular reactivity, and 13 cases showed reactivities between 1 and 50 percent. There was no striking correlation between percentage of cellular reactivity with MAb B72.3 and depth of tumor invasion, histologic tumor grade, or patient age (Table 4) . Secretory endometrium has also been shown to react with MAb B72.3, whereas proliferative phase specimens were negative [22] . This observation prompted a more detailed study of normal endometrial reactivity to help define which physiologic conditions might regulate TAG-72 expression [23] . As shown in Table 5 , all 38 post-ovulatory (secretory) specimens showed cellular reactivity with MAb B72.3 with an average percentage of reactivity of 40.8 ± 28.6 percent. The average percentage specimens of serous effusions and fine-needle aspiration biopsies (FNAB). These types of specimens are likely to contain cancer cells in a significant proportion of cases [27] [28] [29] . When compared to other types of cytologic specimens, effusions and FNABs are notorious for the pitfalls that may be encountered in their interpretation. Effusions may contain reactive but benign mesothelial cells, which may mimic cancer cells. If malignant cells are present, recognition of their origin may be impossible by conventional morphological analysis alone. FNABs may also present significant limitations and diagnostic problems in spite of their current effectiveness and accuracy when interpreted in experienced laboratories. The type of specimen obtained from an FNAB has features of both a tissue section from an open biopsy and purely exfoliated cells. Thus the diagnostic problems posed by an undifferentiated malignant neoplasm in a histologic section may become even more difficult in a fine-needle aspirate.
MAb B72.3 has demonstrated utility as an immunocytologic adjunct to diagnosis of carcinoma in cell block and cytocentrifuge preparations of human serous effusions, with selective reactivity for tumor cells (particularly adenocarcinoma) over reactive mesothelium [30, 31] . Using the ABC-immunoperoxidase method on formalin-fixed, paraffin-embedded cell blocks, MAb B72.3 detected tumor cells in 97 percent of effusions from patients with ovarian serous cystadenocarcinoma (Table 6 ). Ninetythree percent of carcinomas of the uterus and cervix reacted with B72.3, including all 38 endometrial carcinomas (Table 6 ). In addition, MAb B72.3 detected tumor cells in effusions from the majority of patients with adenocarcinoma, including those from lung (non-small cell), breast, and gastrointestinal tract. In contrast, 821 benign effusions showed no reactivity with MAb B72.3 (Table 6 ).
MAb B72.3 has also been used with FNABs and corresponding surgically excised tumors to determine cellular reactivity [29, 311] . Positive The distinction between primary ovarian carcinomas and metastatic carcinoma to the ovary from another site may be difficult using clinical, surgical, and pathologic criteria. Cancers which commonly metastasize to the ovary include carcinoma of the breast, gastrointestinal tract, and genital tract [32] . MAb COL-4, reactive with carcinoembryonic antigen, has been shown to react preferentially with adenocarcinomas of the colon versus a variety of normal tissues [33] . Using ABC-immunoperoxidase techniques, Thor et al. [34] demonstrated differential reactivity of MAb COL-4 with colon carcinoma versus ovarian carcinoma (Table 7) . COL-4 reacted with the vast majority of primary (n = 50) and metastastic (n = 62) colonic carcinomas. In contrast, MAb COL-4 demonstrated little or no reactivity with primary (n = 53) and metastatic (n = 23) carcinomas of the ovary using >10 percent reactive cells as an arbitrary criterion (Table 7) . Hence MAb COL-4 can be used as an immunohistochemical adjunct for the differentiation of ovarian from gastrointestinal adenocarcinomas. aAdapted from [34] bNumbers in parentheses show percentage.
DETECTION OF TAG-72 IN SERA OF CARCINOMA PATIENTS Serum assays employing specific MAbs may be useful in detecting occult carcinoma, monitoring the efficacy of standard therapy, and identifying potential patients for therapy with a specific MAb. A rigorous effort is under way to identify TAAs that can lead to the detection of early ovarian carcinoma, because most patients currently are diagnosed when they already have advanced disease. Several serum assays for ovarian TAA are currently in use, including CEA, CA125, CA15-3 [1, 35] , and human placental alkaline phosphatase [36] .
Serum assays for the detection of CA125 have been shown to be a sensitive marker for the presence of non-mucinous ovarian tumors [35] . Using a value of >65 U/ml, Soper et al. [37] have shown a sensitivity of 90 percent; however, 7 of 47 (15 percent) patients with benign pelvic masses had elevated (>65 U/ml) CA125 in their serum (see below).
An immunoradiometric assay has been developed using MAb B72.3 to quantitate TAG-72 in human serum [38] . In a simultaneous immunoradiometric assay, the mean TAG-72 concentration in 1,099 serum samples from healthy blood donors was 1.83 + 2.03 U/ml. An upper limit of normal of 10 U/ml included 99 percent of healthy blood donors. There was no significant (p < 0.06) effect of sex upon TAG-72 levels in the blood donor group in which age and sex were known (n = 675). This is important in light of the strong expression of TAG-72 by secretory endometrium. Nine of 19 (47 percent) patients with ovarian carcinoma demonstrated TAG-72 positive serum samples; the average TAG-72 level in ovarian carcinoma patients was 65.42 U/ml. Only four of 101 (4 percent) serum samples from patients with benign gastrointestinal disease were elevated, whereas 15 of 26 (58 percent) and 14 of 25 (56 percent) sera from patients with rectal and colon carcinoma, respectively, were positive. The ability of this assay to discriminate between malignant and benign disease suggests its further evaluation for monitoring patients with known or suspected carcinoma [38] , either alone or in combination with preexisting assays.
Soper et al. [37] used the combination of CA125 and TAG-72 serum levels to detect non-mucinous ovarian tumors; 46 percent (18 of 39) of patients with malignant disease had positive levels (>10 U/ml) of TAG-72 and only 2 percent of patients with benign pelvic disease had positive serum levels of TAG-72. When TAG-72 was used in combination with CAI 25, the specificity was increased to 98 percent.
A prospective study [39] using the combination of TAG-72 and CA125 is currently being conducted on 5,000 apparently healthy women to determine whether use of a combination of markers might permit cost-effective screening for occult malignancy in an apparently healthy population.
USE OF RADIOLABELED MAb B72.3 FOR THE LOCALIZATION
OF METASTATIC CARCINOMA Studies have demonstrated that radiolabled MAbs to TAAs can detect carcinoma lesions using gamma scanning. These studies were conducted using MAbs to carcinoembryonic antigen. MAbs 1083-17-lA and 19-9, and MAbs to human milk fat globule membranes [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] .
The administration of 311-labeled B72.3 in patients with colorectal carcinoma and the quantitative evaluation of its reactivity with tumor versus a wide range of normal tissues has been recently reported [52] . Gamma scanning followed by a comprehensive direct examination of tumor and a variety of normal tissues was achieved. Specimens were weighed and placed in a gamma counter to determine counts per minute (cpm) per gram values. Fixed biopsy specimens were analyzed for (a) percentage of tumor cells present and (b) TAG-72 antigen-positive cells using MAb B72.3 and ABCimmunoperoxidase techniques. Positive gamma scans (confirmed at surgery) were observed in 14 of 27 patients and in 10 of 20 patients in whom direct examination of tissues was available. This result is rather promising considering that "'I was used, since this isotope is not optimal for gamma scanning. Gamma scans accurately identified tumor lesions in the liver, bone, orbit, rectum, colon, cecum, pelvis, and diffusely in the peritoneal cavity. No anaphylaxis, serum sickness, bone marrow suppression, or other toxicity was observed [52] .
The radiolocalization index (RI) value is defined as the ratio of the uptake of stimultaneous administration of '251I-labeled B72.3 intravenously, and '311-labeled B72.3 intraperitoneally, and (c) define the pharmacokinetics of plasma clearance of both intraperitoneally and intravenously administered radiolabeled MAb B72.3.
All patients were part of a pre-existing NCI Surgery Branch protocol for the surgical resection of suspected or confirmed peritoneal metastatic colorectal carcinoma followed by intraperitoneal administration of therapeutic agents. Four to seven days before surgery, all patients were administered 1311-labeled B72.3 intraperitoneally via a catheter. All patients received between 0.76 and 1.2 mg of IgG and between 5.0 and 1i0.0 MCi '3'1, with specific activities of s31nn-B72.3 IgG ranging from 6.6 to 1.0 mCi/mg [55, 56] .
On the day of or prior to surgery, patients were scanned with a gamma camera; all scan results were interpreted before surgery. Gamma scans of seven of ten patients showed clearly discernable concentrations of radiolabeled MAb in various distinct regions of the peritoneum. In all such cases, these lesions were identified at surgery as tumor and later confirmed as carcinoma via light microscopic examination. A representative positive gamma scan is shown in Figs. 1IA-I C (patient MM) . Note the accumulation of radiolabeled MAb in the peritoneal gutters immediately after intraperitoneal MAb administration (Fig. 1nA) and at three days after MAb administration (Fig. 1B) . The gamma scan at six days post-MAb administration, however, aAdapted from [56] shows MAb concentration in distinct areas of the peritoneum (confirmed as carcinoma at surgery and by light microscopic examination). These findings can be contrasted with the negative gamma scans of patient RK (Figs. 1 D-1 F) ; who had no intraperitoneal disease [56] . Three of the ten patients studied were positive for MAb localization via gamma scanning (confirmed at surgery) but were negative for tumor via CT scan and X-ray studies. Lesions as small as approximately 1.5 cm in diameter were clearly defined by gamma scans. All specimens removed at surgery were analyzed for cpm per g of tissue. Specimens were then fixed, embedded, and analyzed for percentage of carcinoma cells present. Table 8 shows the RI values (based on % ID MAb uptake per kg of tumor versus % ID MAb uptake per kg of normal tissue) of the biopsy specimens of tumor and normal tissues from the ten patients receiving intraperitoneally administered MAb B72.3. An RI of >3 was arbitrarily chosen as a positive radiolabeled uptake; 83 of 112 (74 percent) of carcinoma lesions showed RI values -3. In some patients with a large tumor burden, as much as 40 percent of the injected dose was bound to carcinoma. Note that of the 29 lesions negative for MAb uptake, 11 were from patient MG, the only patient in whom all tumor lesions were negative for TAG-72 antigen expression. Of the 95 histologically confirmed normal tissues biopsied, all but one demonstrated RI values <3 (Table 8 ). The one exception had an RI of 3.5 and was a histologically normal spleen from patient JB. Interestingly, this patient had the highest level of circulating antigen '31I-B72.3 IgG immune complex as determined by HPLC and RIA.
The other 94 normal tissue biopsies with RI values <3 were from numerous sites, including colon, ileum, duodenum, pancreas, liver, spleen, lymph node, kidney, ovary, and fallopian tube; the vast majority of RI values ranged from 0.5 to 1.5 [56] .
Studies were next conducted to determine the relative efficacies of intraperitoneally versus intravenously administered MAb to localize tumor lesions [56] . Patients were concomitantly administered "3'I-labeled B72.3 intraperitoneally and '25I-labeled B72.3 There are several diagnostic implications from these studies. Radiolabeled B72.3 may now be considered for use in the localization of suspected colorectal or ovarian carcinoma lesions. Carcinoma can be detected by intraperitoneally administered "3'I-labeled B72.3 when in some cases, other radiologic procedures, including CT scan, may not detect lesions [56] . Ovarian carcinoma, because its metastases are often limited as implants in the peritoneum, is an ideal type of tumor for immunodiagnosis and immunotherapy using intraperitoneally administered MAb. Based on intraperitoneal administration of radiolabeled B72.3 in colorectal patients and early reports in ovarian carcinoma patients [53, 54] In summary, monoclonal antibodies may make significant contributions to the management of gynecologic malignancies. Because of the asymptomatic nature of ovarian carcinoma, early diagnosis is essential to prognosis. Through the use of serum assays, MAbs may identify asymptomatic patients. Radioimaging with '3'I-labeled MAb has detected carcinoma lesions that otherwise escaped the usual radiologic detection methods. Due to the suboptimal imaging characteristics of '3'I, the use of low-energy gamma emitters such as "'In, 99mTc, or 1231, which have favorable scanning properties, will result in better diagnostic gamma scans. Immunohistochemical assays and serum assays may be important in the selection of appropriate patients whose tumors demonstrate high levels of a given tumor antigen.
